Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2001-12-12
2002-10-01
Jones, Dwayne C. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S604000, C514S605000
Reexamination Certificate
active
06458845
ABSTRACT:
FIELD OF INVENTION
Cardiovascular diseases are the leading cause of death in the U.S., accounting annually for more than one million deaths. Atherosclerosis is the major contributor to coronary heart disease and a primary cause of non-accidental death in Western societies. Since the prevention of atherosclerosis is an enormous unmet medical need, considerable effort has been made in defining the etiology and potential treatment of atherosclerosis and its consequences, including myocardial infarction, angina, organ failure and stroke. Despite this effort, there are many unanswered questions including how and when atherosclerotic lesions become life-threatening, the best point of intervention, and how to detect and monitor the progression of lesions.
There is widespread agreement that multiple risk factors contribute to atherosclerosis including hypertension, elevated total serum cholesterol, high levels of low density lipoprotein (“LDL”) cholesterol, low levels of high density lipoprotein (“HDL”) cholesterol, diabetes mellitus, severe obesity, and cigarette smoking. To date, treatment of atherosclerosis has been narrowly focused on treating elevated cholesterol levels and modifying lipids has become the major focus of treatment and research.
However, recent studies have indicated that 40% of deaths due to coronary disease occurred in men with total cholesterol levels of below 220 mg/dl. It is thus obvious that too great an emphasis is being placed on lipid lowering. Indeed, only 30% of patients with atherosclerosis have elevated lipid levels, indicating that other pathogenic factors are involved. A logical scenario for future therapies and preventive measures should therefore include a multidisciplinary approach consisting of diet modification, HMG-CoA reductase inhibition and novel therapies aimed directly at plaque growth and stability.
The initial lesion in atherosclerosis is the fatty streak, which arises from cholesteryl esters maintained as lipid droplets inside macrophage-derived foam cells. Macrophages down-regulate their LDL receptors and instead express mRNA and undergo new protein synthesis for a novel receptor for modified LDL. This receptor recognizes all modified forms of low-density lipoprotein and has come to be known as the macrophage scavenger receptor (“MSR”). If the macrophage is present in an environment that is continually generating modified LDL, it will accumulate lipid droplets of cholosteryl esters, continuing until the macrophage dies from its toxic lipid burden. The released lipid then forms the acellular necrotic core of the atherosclerotic lesion. Subsequent recruitment of fibroblasts, vascular smooth muscle cells and circulating monocytes and T-lymphocytes complete the inflammatory response and formation of the mature atherosclerotic plaque. Macrophage-derived foam cells are concentrated in the shoulders of plaques, where their secreted proteases and collagenases may contribute to plaque rupture which may lead to a fatal thrombotic event.
Plaque regression, a function of the dynamic balance among initiation, progression, stabilization and removal of plaque constituents, has been unequivocally demonstrated in humans as well as in numerous animal models. Multiple regression studies in non-human primates have shown that even relatively advanced lesions regress over time when atherogenic dietary stimuli are discontinued or pharmacological regimens are initiated.
Inhibition of lipid accumulation within macrophage-derived foam cells by utilizing MSR antagonists is expected to prevent plaque initiation, retard plaque progression, and initiate plaque regression through the process of “reversed cholesterol transport” to acceptor HDL. Thus, MSR antagonists provide a unique approach towards the pharmacotherapy of cardiovascular diseases such as atherosclerosis, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure, and hypercholesterolemia.
SUMMARY OF THE INVENTION
The present invention involves sulfonamidobenzanilide compounds represented by Formula (I) hereinbelow and their use as macrophage scavenger receptor (“MSR”) antagonists which are useful in the treatment of a variety of cardiovascular diseases including but not limited to atherosclerosis, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
The present invention further provides methods for antagonizing the macrophage scavenger receptor in animals, including humans, comprising administering to an animal in need of treatment an effective amount of a compound of Formula (I), indicated hereinbelow.
The present invention further provides methods of inhibiting lipid accumulation within macrophage-derived foam cells.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of the present invention are selected from Formula (I) hereinbelow:
wherein:
R
1
, and R
2
are independently selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkyl, acyl, aroyl, haloalkyl, halo, carboxy, carboalkoxy, carbamyl, alkylcarbamyl, arylcarbamyl, cyano, alkoxy, hydroxyl, phenylazo, amino, nitro, alkylamino, arylamino, arylalkylamino, acylamino, aroylamino, alkylthio, arylalkylthio, arylthio, alkysulfinyl, arylsulfinyl, arylalkylsulfinyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl, sulfamyl, arylsulfonamido, and alkylsulfonamido;
or the R
1
moiety represents a fused ring forming a benzothiophene, naphthalene, quinoline, or isoquinoline with the ring it substitutes;
or (R
1
)
n
and the ring it substitutes represents a heterocycle selected from the group consisting of thiophene, furan, pyridine, pyrimidine, and pyrazine, and benzo analogs thereof; and
R
3
is independently selected from the group consisting of alkyl, haloalkyl, R
1
aryl and R
1
aralkyl, and R
1
substituted heterocycles selected from the group consisting of thiophene, furan, pyridine, pyrimidine, pyrazine, imidazole, and thiazole, and benzo analogs thereof;
or R
3
and the ring it substitutes represents a R
1
substituted heterocycle selected from the group consisting of thiophene, furan, pyridine, pyrimidine, and pyrazine, and benzo analogs thereof.
As used herein, “alkyl” refers to an optionally substituted hydrocarbon group joined together by single carbon-carbon bonds. Preferred alkyl substituents are as indicated throughout. The alkyl hydrocarbon group may be linear, branched or cyclic, saturated or unsaturated.
As used herein, “aryl” refers to an optionally substituted aromatic group with at least one ring having a conjugated pi-electron system, containing up to two conjugated or fused ring systems. “Aryl” includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted. Preferred aryl substituents are as indicated throughout.
The compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds and diastereomers are, contemplated to be within the scope of the present invention.
Preferred compounds of the present invention are selected from the group consisting of:
N-Phenyl-2-(3-trifluoromethylphenylsulfonamido)benzamide,
5-Bromo-N-(3,4-dichlorophenyl)-2-(3-trifluoromethylphenylsulfonamido)benzamide,
N-(4-Chlorophenyl)-2-(2-fluorophenylsulfonamido)benzamide,
5-Bromo-N-(3-trifluoromethylphenyl)-2-(5-chloro-2-thienylsulfonamido)benzamide,
5-Chloro-N-(4-chlorophenyl)-2-(5-chloro-2- thienylsulfonamido)benzamide,
N-(3-Chloro-4-methoxyphenyl)-2-(4-methoxy phenylsulfonamido)benzamide,
N-Phenyl-2-(2-fluorophenylsulfonamido)benzamide,
N-(4-Chlorophenyl-2-(3-trifluoromethylphenylsulfonamido)benzamide,
N-Phenyl-2-(4-methoxyphenylsulfonamido)benzamide,
N-(4-Chlorophenyl-2-(3-trifluoromethylphenylsulfonamido)-4-methoxy-benzamide,
N-(3-Chloro-4-methoxyphenyl-2-(3-trifluoromethylphenylsulfonamido)-4-methoxybenzamide,
N-(3,4-Dichlorophenyl)-2-(2-fluorophenylsulfonamido)-5-methoxybenzamide,
N-(4-chl
Franz Robert G.
Gaitanopoulos Dimitri E.
Weinstock Joseph
Jones Dwayne C.
Kinzig Charles M.
McCarthy Mary E.
Simon Soma G.
SmithKline Beecham Corporation
LandOfFree
Macrophage scavenger receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Macrophage scavenger receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrophage scavenger receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2921934